(4S,5S)-5-(5-Chloro-2-thienyl)-4-methyl-2-oxazolidinone | 943918-06-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: (4S,5S)-5-(5-Chloro-2-thienyl)-4-methyl-2-oxazolidinone
• 英文别名: (4S,5S)-5-(5-chlorothiophen-2-yl)-4-methyl-1,3-oxazolidin-2-one
• CAS: 943918-06-7
• 化学式: C₈H₈ClNO₂S
• 分子量: 217.67
• InChiKey: LMPNQKMAEJOEIO-FFWSUHOLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  66.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS
  申请人：ALI Amjad

  公开号：US20110178059A1

  公开（公告）日：2011-07-21

  Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.

  具有公式I结构的化合物，包括该化合物的药物可接受的盐，是CETP抑制剂，有助于提高HDL胆固醇，降低LDL胆固醇，并用于治疗或预防动脉粥样硬化。该化合物具有由单键连接的3个环形基团，例如三苯基，直接连接到公式I的环上或连接到位置B上。
• 1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors
  申请人：Ali Amjad

  公开号：US20090137548A1

  公开（公告）日：2009-05-28

  Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B.

  具有I式结构的化合物，包括化合物的药学可接受盐，是CETP抑制剂，并且有助于提高HDL胆固醇，降低LDL胆固醇，并用于治疗或预防动脉硬化。这些化合物具有由单键连接的3个环状基团，例如三苯基，它们直接连接在I式环上或连接在B位置。
• CETP inhibitors
  申请人：Merck Sharp & Dohme Corporation

  公开号：EP2415759A1

  公开（公告）日：2012-02-08

  Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a -CH2-.

  具有式 I 结构的化合物，包括这些化合物的药学上可接受的盐，是 CETP 抑制剂，可用于提高高密度脂蛋白胆固醇、降低低密度脂蛋白胆固醇以及治疗或预防动脉粥样硬化： 在式 I 的化合物中，B 或 R2 是具有正芳基、杂环基、苯并杂环基或苯环烷基取代基的苯基，五元环上的另一个位置具有直接连接到环上或通过-CH2-连接到环上的芳基、杂环基、环烷基、苯并杂环基或苯环烷基取代基。
• ANACETRAPIB AND OTHER CETP INHIBITPRS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1765793B1

  公开（公告）日：2012-09-26
• 1,3-OXAZOLIDIN-2-ONE DERIVATIVES USEEFUL AS CETP INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2029560B1

  公开（公告）日：2013-04-24